NO20073655L - Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav - Google Patents

Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav

Info

Publication number
NO20073655L
NO20073655L NO20073655A NO20073655A NO20073655L NO 20073655 L NO20073655 L NO 20073655L NO 20073655 A NO20073655 A NO 20073655A NO 20073655 A NO20073655 A NO 20073655A NO 20073655 L NO20073655 L NO 20073655L
Authority
NO
Norway
Prior art keywords
antibodies
receptor alpha
antibody
heavy chain
variable
Prior art date
Application number
NO20073655A
Other languages
English (en)
Inventor
Adelbert Grossmann
Ralf Schumacher
Paul Parren
Yvo Graus
Frank Rebers
Martine Van Vugt
Kay-Gunnar Stubenrauch
Jan Van De Winkel
Josef Endl
Maria Elena Fuentes
Jorg Regula
Sebastian Neumann
Stefan Seeber
Jan Stracke
Sandra Vereecken-Verploegen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20073655L publication Critical patent/NO20073655L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et antistoff som binder til IL-13Ra1, hemmer IL-13 bioaktivitet og omfatter en variabel tung og en variabel lett kjede, karakterisert ved at den variable tung kjede aminosyresekvensen CDR3 av nevnte antistoff er valgt fra gruppen bestående av tung kjede CDR3-sekvensene av SEKV ID NR: 1, 3, 5, 7 eller 9 er anvendelige ved behandling av astma og allergiske sykdommer.
NO20073655A 2005-01-03 2007-07-17 Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav NO20073655L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05000003 2005-01-03
EP05002229 2005-02-03
PCT/EP2006/000005 WO2006072564A1 (en) 2005-01-03 2006-01-02 Antibodies against il-13 receptor alpha 1 and uses thereof

Publications (1)

Publication Number Publication Date
NO20073655L true NO20073655L (no) 2007-08-02

Family

ID=36199730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073655A NO20073655L (no) 2005-01-03 2007-07-17 Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav

Country Status (19)

Country Link
US (2) US7807158B2 (no)
EP (1) EP1836226B1 (no)
JP (1) JP5086098B2 (no)
KR (1) KR100934894B1 (no)
AR (1) AR051888A1 (no)
AT (1) ATE513855T1 (no)
AU (1) AU2006204480B2 (no)
BR (1) BRPI0606368A2 (no)
CA (1) CA2592614C (no)
CR (1) CR9209A (no)
IL (1) IL184205A0 (no)
MA (1) MA29226B1 (no)
MX (1) MX2007008128A (no)
NO (1) NO20073655L (no)
NZ (1) NZ556126A (no)
RU (1) RU2413736C2 (no)
SG (1) SG172504A1 (no)
TW (2) TW200902555A (no)
WO (1) WO2006072564A1 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008054606A2 (en) * 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
JP2010507366A (ja) * 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド インターロイキン−１３受容体α１の抗体アンタゴニスト
WO2008060814A2 (en) * 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
RU2009148891A (ru) 2007-06-01 2011-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Очистка иммуноглобулина
CA2693611A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
MX2010003622A (es) 2007-10-12 2010-04-14 Hoffmann La Roche Expresion proteinica a partir de acidos nucleicos multiples.
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2407603T3 (es) 2007-12-15 2013-06-13 F. Hoffmann-La Roche Ag Ensayo de distinción
EP3702371B1 (en) * 2009-03-25 2022-11-02 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
EP2431463A4 (en) * 2009-05-13 2012-12-26 Shionogi & Co TESTS FOR VISCERAL ADIPOSITAS AND ITS USE
US9289699B2 (en) 2009-07-30 2016-03-22 Hoffmann-La Roche Inc. Moveable chromatography column separator
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
CN103980346A (zh) 2009-10-01 2014-08-13 弗·哈夫曼-拉罗切有限公司 多步骤的最终过滤
US9957331B2 (en) 2009-10-19 2018-05-01 Hoffmann-La Roche Inc. Non-cross-reactive anti IgG antibodies
US9150641B2 (en) 2009-12-22 2015-10-06 Hoffmann—La Roche Inc. Sequence dependent aggregation
CA2806851C (en) 2010-08-17 2019-12-03 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
WO2012104278A1 (en) 2011-02-02 2012-08-09 F. Hoffmann-La Roche Ag Chromatography column support
US10654916B2 (en) 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR102248581B1 (ko) 2013-07-04 2021-05-06 에프. 호프만-라 로슈 아게 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
PT3613432T (pt) 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
EP3201230B1 (en) 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
US10066017B2 (en) 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
WO2017032686A1 (en) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
JP7073253B2 (ja) * 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2018011405A1 (en) * 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
US11292850B2 (en) 2018-03-21 2022-04-05 ALX Oncology Inc. Antibodies against signal-regulatory protein α and methods of use
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
EP3947457A1 (en) 2019-03-26 2022-02-09 ASLAN Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
EP4590335A1 (en) 2022-08-26 2025-07-30 ASLAN Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
EP4594352A1 (en) 2022-09-06 2025-08-06 ASLAN Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0907730B1 (en) 1995-10-23 2009-10-07 Zenyth Operations Pty Ltd Haemopoietin receptor and genetic sequences encoding same
US5843659A (en) * 1996-03-21 1998-12-01 Apoptosis Technology, Inc. Apoptosis gene EI24, compositions, and methods of use
EP1449851A4 (en) 2001-11-27 2005-11-16 Mochida Pharm Co Ltd NEUTRALIZING ANTIBODIES OF IL13 ALPHA RECEPTOR 1
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
CA2480059C (en) * 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
EP1613774A2 (en) * 2003-03-10 2006-01-11 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
CN1849138B (zh) * 2003-07-15 2011-11-30 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体

Also Published As

Publication number Publication date
EP1836226A1 (en) 2007-09-26
NZ556126A (en) 2008-09-26
JP2008526187A (ja) 2008-07-24
CA2592614A1 (en) 2006-07-13
MX2007008128A (es) 2007-07-20
CR9209A (es) 2007-08-28
HK1112006A1 (en) 2008-08-22
AU2006204480B2 (en) 2011-06-09
US20110086026A1 (en) 2011-04-14
TWI306862B (en) 2009-03-01
KR100934894B1 (ko) 2010-01-07
US20060263356A1 (en) 2006-11-23
BRPI0606368A2 (pt) 2009-06-23
TW200902555A (en) 2009-01-16
TW200635945A (en) 2006-10-16
RU2413736C2 (ru) 2011-03-10
AR051888A1 (es) 2007-02-14
KR20070091180A (ko) 2007-09-07
AU2006204480A1 (en) 2006-07-13
EP1836226B1 (en) 2011-06-22
CA2592614C (en) 2015-04-14
ATE513855T1 (de) 2011-07-15
WO2006072564A1 (en) 2006-07-13
MA29226B1 (fr) 2008-02-01
JP5086098B2 (ja) 2012-11-28
IL184205A0 (en) 2007-10-31
RU2007129676A (ru) 2009-02-10
US7807158B2 (en) 2010-10-05
SG172504A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
NO20073655L (no) Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
LTPA2017038I1 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
NZ607711A (en) Antibodies directed to her-3 and uses thereof
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
RU2013138469A (ru) АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
NO20090224L (no) Anti-IL-6 monoklonale antistoffer og anvendelser derav
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
ATE395364T1 (de) Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
JP2012507294A5 (no)
PE20120429A1 (es) Proteinas de enlace de miostatina
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
PE20080036A1 (es) Anticuerpos humanos para la interleucina-13 (il13)
RU2011144166A (ru) Способы применения антител к il-22 человека
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
JP2007525465A5 (no)
WO2011064257A3 (de) Monospezifische polypeptidreagenzien
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application